Download PDF
Thorac Cardiovasc Surg
DOI: 10.1055/a-2331-2585
Original Cardiovascular

Surgical and Histopathological Results in Carotid Body Tumors

Mehmet Işık 
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Meram Medical Faculty Hospital, NEÜ Meram Tıp Fakültesi Kalp ve Damar Cerrahisi, Konya, Turkey
,
Fahriye Kılınç
2   Department of Pathology, Necmettin Erbakan Üniversitesi, Konya, Turkey
,
Yüksel Dereli
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Meram Medical Faculty Hospital, NEÜ Meram Tıp Fakültesi Kalp ve Damar Cerrahisi, Konya, Turkey
,
Ömer Tanyeli
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Meram Medical Faculty Hospital, NEÜ Meram Tıp Fakültesi Kalp ve Damar Cerrahisi, Konya, Turkey
,
Serkan Yıldırım
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Meram Medical Faculty Hospital, NEÜ Meram Tıp Fakültesi Kalp ve Damar Cerrahisi, Konya, Turkey
,
Rabia Alakuş
2   Department of Pathology, Necmettin Erbakan Üniversitesi, Konya, Turkey
,
Hamdi Arbağ
3   Department of Ear Nose and Throat Surgery, Necmettin Erbakan University, Konya, Turkey
,
Niyazi Görmüş
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Meram Medical Faculty Hospital, NEÜ Meram Tıp Fakültesi Kalp ve Damar Cerrahisi, Konya, Turkey
› Author Affiliations
› Further Information
    Permissions and Reprints All articles of this category

Abstract

Objective The possible relationships between the histopathological findings of carotid body tumors and age, gender, tumor diameter, and Shamblin classification were investigated. In addition, preoperative embolization status, development of neurological complications, need for vascular reconstruction, hemoglobin change, and discharge time were examined and the effects of these variables on each other were analyzed.

Methods Between 2008 and 2022, 46 cases who underwent carotid body tumor excision were examined retrospectively. The cases were followed for an average of 81 months postoperatively. Histopathological materials were reexamined and the effect of categorical variables was analyzed.

Results Mean tumor diameter was 3.55 ± 1.26 cm, mean discharge time was 3.91 ± 2.37 days, and mean hemoglobin change was 1.86 ± 1.25. Neurological complications developed in 13% of cases. The amount of hemoglobin change was significantly (p = 0.003) higher in those who developed neurological complications, whereas the tumor diameter and discharge time were found to be insignificantly higher. Surgical complications requiring vascular repair occurred in 10.8% of cases. Tumor diameter (p = 0.017) and hemoglobin change (p = 0.046) were significantly higher in these patients. There were significant correlations between higher Shamblin classification and tumor diameter, discharge time, postoperative hemoglobin value, and number of surgical and neurological complications. No significant difference was found between Ki-67, capsular invasion, mitosis, pleomorphism, prominent nucleoli, mean island diameter, and tendency of islands to merge with categorical variables.

Conclusion As the tumor diameter increases, the operation becomes more difficult and the postoperative complication rate increases. We think that subadventitial and capsular removal of the tumor is effective in preventing recurrence. To reach a histopathological conclusion, a larger series of studies including tumors with high Ki-67 and mitosis rates, large size, and one or more of the criteria for necrosis are needed.

Keywords

carotid body tumors - carotid paragangliomas - histopathological results - neuroendocrine tumors - surgical complications

Supplementary Material



Publication History

Received: 13 April 2024

Accepted: 21 May 2024

Accepted Manuscript online:
22 May 2024

Article published online:
12 June 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Nazari I, Aarabi Moghaddam F, Zamani MM, Salimi J. Clinical characteristics and remedies in 45 Iranians with carotid body tumors. Acta Med Iran 2012; 50 (05) 339-343
    PubMedGoogle Scholar
  • 2 Dimakakos PB, Kotsis TE. Carotid body paraganglioma: review and surgical management. Eur J Plast Surg 2001; 24: 58-65
    CrossrefPubMedGoogle Scholar
  • 3 Kruger AJ, Walker PJ, Foster WJ, Jenkins JS, Boyne NS, Jenkins J. Important observations made managing carotid body tumors during a 25-year experience. J Vasc Surg 2010; 52 (06) 1518-1523
    CrossrefPubMedGoogle Scholar
  • 4 Luna-Ortiz K, Rascon-Ortiz M, Villavicencio-Valencia V, Granados-Garcia M, Herrera-Gomez A. Carotid body tumors: review of a 20-year experience. Oral Oncol 2005; 41: 56-61
    CrossrefPubMedGoogle Scholar
  • 5 Shamblin WR, ReMine WH, Sheps SG, Harrison EG. Jr. Carotid body tumor (chenodectoma). Clinical pathologic analysis of ninety cases. Am J Surg 1971; 122 (06) 732-739
    CrossrefPubMedGoogle Scholar
  • 6 Ma D, Liu L, Yao H. et al. A retrospective study in management of carotid body tumour. Br J Oral Maxillofac Surg 2009; 47 (06) 461-465
    CrossrefPubMedGoogle Scholar
  • 7 Kotelis D, Rizos T, Geisbüsch P. et al. Late outcome after surgical management of carotid body tumors from a 20-year single-center experience. Langenbecks Arch Surg 2009; 394 (02) 339-344
    CrossrefPubMedGoogle Scholar
  • 8 Power AH, Bower TC, Kasperbauer J. et al. Impact of preoperative embolization on outcomes of carotid body tumor resections. J Vasc Surg 2012; 56 (04) 979-989
    CrossrefPubMedGoogle Scholar
  • 9 Gilbo P, Morris CG, Amdur RJ. et al. Radiotherapy for benign head and neck paragangliomas: a 45-year experience. Cancer 2014; 120 (23) 3738-3743
    CrossrefPubMedGoogle Scholar
  • 10 Duet M, Sauvaget E, Pételle B. et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 2003; 44 (11) 1767-1774
    PubMedGoogle Scholar
  • 11 Kawai A, Healey JH, Wilson SC, Huvos AG, Yeh SDJ. Carotid body paraganglioma metastatic to bone: report of two cases. Skeletal Radiol 1998; 27 (02) 103-107
    CrossrefPubMedGoogle Scholar
  • 12 Westerband A, Hunter GC, Cintora I. et al. Current trends in the detection and management of carotid body tumors. J Vasc Surg 1998; 28 (01) 84-92 , discussion 92–93
    CrossrefPubMedGoogle Scholar
  • 13 Fruhmann J, Geigl JB, Konstantiniuk P, Cohnert TU. Paraganglioma of the carotid body: treatment strategy and SDH-gene mutations. Eur J Vasc Endovasc Surg 2013; 45 (05) 431-436
    CrossrefPubMedGoogle Scholar
  • 14 Gad A, Sayed A, Elwan H. et al. Carotid body tumors: a review of 25 years experience in diagnosis and management of 56 tumors. Ann Vasc Dis 2014; 7 (03) 292-299
    CrossrefPubMedGoogle Scholar
  • 15 Texakalidis P, Charisis N, Giannopoulos S. et al. Role of preoperative embolization in carotid body tumor surgery: a systematic review and meta-analysis. World Neurosurg 2019; 129: 503-513.e2
    CrossrefPubMedGoogle Scholar
  • 16 Qin RF, Shi LF, Liu YP. et al. Diagnosis and surgical treatment of carotid body tumors: 25 years' experience in China. Int J Oral Maxillofac Implants 2009; 38 (07) 713-718
    CrossrefPubMedGoogle Scholar
  • 17 Robertson V, Poli F, Hobson B, Saratzis A, Ross Naylor A. A systematic review and meta-analysis of the presentation and surgical management of patients with carotid body tumours. Eur J Vasc Endovasc Surg 2019; 57 (04) 477-486
    CrossrefPubMedGoogle Scholar
  • 18 Sajid MS, Hamilton G, Baker DM. Joint Vascular Research Group. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg 2007; 34 (02) 127-130
    CrossrefPubMedGoogle Scholar
  • 19 Makeieff M, Raingeard I, Alric P, Bonafe A, Guerrier B, Marty-Ane Ch. Surgical management of carotid body tumors. Ann Surg Oncol 2008; 15 (08) 2180-2186
    CrossrefPubMedGoogle Scholar
  • 20 Wang YH, Yang J, Zhong H. et al. Prevalence, characteristics, evaluation, and management of carotid body tumors: systematic analysis based on available evidence. J Vasc Surg 2024
    PubMedGoogle Scholar
  • 21 Erentuğ V, Bozbuğa NU, Sareyyüpoğlu B. et al. The surgical approaches in carotıd body tumors. Turk Gogus Kalp Damar Cerrahisi Derg 2004; 12 (04) 277-279
    PubMedGoogle Scholar
  • 22 Thompson LDR, Gill AJ, Asa SL. et al. Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol 2021; 110: 83-97
    CrossrefPubMedGoogle Scholar
  • 23 Kimura N, Takayanagi R, Takizawa N. et al; Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2014; 21 (03) 405-414
    CrossrefPubMedGoogle Scholar
  • 24 Koh JM, Ahn SH, Kim H. et al. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 2017; 12 (11) e0187398
    CrossrefPubMedGoogle Scholar
  • 25 Fishbein L, Del Rivero J, Else T. et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma. Pancreas 2021; 50 (04) 469-493
    CrossrefPubMedGoogle Scholar